Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 2/20 | 0.48 |
| ▸ | TP53 | P04637 | 4/20 | 0.46 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.46 |
| ▸ | BRAF | P15056 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | KDM1A | O60341 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.40 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.40 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.40 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.40 |
| ▸ | MTTP | P55157 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7601988 | 0.83 | TP53 (0.44) | CTSSTP53RXFP1BRAFPDE4B | |
| SCHEMBL7602331 | 0.82 | TP53 (0.50) | CTSSTP53RXFP1BRAFKDM1A | |
| SCHEMBL6990055 | 0.82 | TP53 (0.50) | CTSSTP53RXFP1BRAFLMNA | |
| SCHEMBL7600009 | 0.81 | TP53 (0.49) | CTSSTP53RXFP1PDE4B | |
| SCHEMBL7607715 | 0.80 | TP53 (0.44) | CTSSTP53RXFP1BRAFLMNA | |
| SCHEMBL7089224 | 0.79 | TP53 (0.49) | CTSSTP53RXFP1BRAFTHRB | |
| SCHEMBL6288117 | 0.75 | ATF1 (0.55) | TP53RXFP1BRAFLMNA | |
| SCHEMBL7647047 | 0.71 | FLT3 (0.45) | CTSSTP53RXFP1BRAFTHRB | |
| SCHEMBL7145186 | 0.70 | FLT3 (0.43) | CTSSTP53RXFP1BRAFLMNA | |
| SCHEMBL6990873 | 0.67 | NFKB1 (0.57) | LMNAKDM1AHDAC1ADORA3ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020183335-A1 | Administering disubstituted pyrimidine-5-carboxamide derivatives for therapy of disorders responsive to the modulation of the potassium channels | BRISTOL-MYERS SQUIBB COMPANY | 2002-12-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020183335-A1 | Administering disubstituted pyrimidine-5-carboxamide derivatives for therapy of disorders responsive to the modulation of the potassium channels | KCNQ5, KCNQ1, KCNQ2 | CTSS 2132/4885TP53 4790/4885RXFP1 764/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.